Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gemcitabine for Marginal Zone Lymphoma

This study has been terminated.
(poor accrual and response less than expected on interim analysis)
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Cheolwon Suh, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT00337259
First received: June 14, 2006
Last updated: February 13, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2009
  Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)